The Investor
11 Aug 2026, 16:25
Bristol Myers Squibb Plans $2.3 Billion Houston Manufacturing Campus
Bristol Myers Squibb (NYSE: BMY) announced plans to invest approximately $2.3 billion in a new manufacturing campus in Houston, Texas, expanding the pharmaceutical company’s U.S. production capacity.
The roughly 600,000-square-foot facility will be located at Generation Park and is expected to create nearly 500 skilled jobs. The modular, multi-modal campus will be capable of manufacturing several types of medicines, including small molecules, biologics and antibody-drug conjugates.
The project represents another step in Bristol Myers Squibb’s broader commitment to invest $40 billion in the United States over five years across manufacturing, research and development, and technology.
Construction is also expected to support approximately 2,000 construction and indirect jobs between 2027 and 2030. BMS said the facility is being designed for long-term expansion and increased automation, allowing manufacturing capacity to evolve alongside the company’s drug pipeline.
For Bristol Myers Squibb, the Houston investment strengthens domestic manufacturing capacity and supply-chain resilience while providing additional infrastructure to support future medicine launches.
Bristol Myers Squibb (NYSE: BMY) announced plans to invest approximately $2.3 billion in a new manufacturing campus in Houston, Texas, expanding the pharmaceutical company’s U.S. production capacity.
The roughly 600,000-square-foot facility will be located at Generation Park and is expected to create nearly 500 skilled jobs. The modular, multi-modal campus will be capable of manufacturing several types of medicines, including small molecules, biologics and antibody-drug conjugates.
The project represents another step in Bristol Myers Squibb’s broader commitment to invest $40 billion in the United States over five years across manufacturing, research and development, and technology.
Construction is also expected to support approximately 2,000 construction and indirect jobs between 2027 and 2030. BMS said the facility is being designed for long-term expansion and increased automation, allowing manufacturing capacity to evolve alongside the company’s drug pipeline.
For Bristol Myers Squibb, the Houston investment strengthens domestic manufacturing capacity and supply-chain resilience while providing additional infrastructure to support future medicine launches.
